Showing results (351-360 of 938) with videos related to
Sort By:
Pageof 94
Clinical Neuropharmacology|April 1, 1997
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesiasF Stocchi, G Nordera, C D MarsdenBiofeedback and Self-Regulation|December 1, 1991
EMG biofeedback treatment of torticollis: a controlled outcome studyM Jahanshahi, G Sartory, C D MarsdenJournal of the Neurological Sciences|March 1, 1993
Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in ratsL Cicin-Sain, P JennerNeuroscience Letters|May 2, 2000
Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor releaseK S McNaught, P JennerJournal of Neurochemistry|December 3, 1999
Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-culturesK S McNaught, P JennerInternational Journal of Clinical Pharmacology and Biopharmacy|July 1, 1975
Metabolic N-oxidation products of aliphatic amines as potential mediators in amine pharmacologyJ W Gorrod, P JennerNeuroscience Letters|January 4, 2001
Proteasomal function is impaired in substantia nigra in Parkinson's diseaseK S McNaught, P JennerBiochemical Pharmacology|September 7, 2000
Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activationK S McNaught, P JennerAnnals of Neurology|September 28, 1998
Understanding cell death in Parkinson's diseaseP Jenner, C W OlanowPageof 94